Apple Restores Telegram to App Store After Content Policy Violation 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Jetstar to Charge for Overhead Cabin Bags From February 
Dublin, March 16, 2018 -- The "Global Smoking Cessation Partnering 2012 to 2018" report has been added to ResearchAndMarkets.com's offering.
The Global Smoking Cessation Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Executive Summary
Chapter 1 - Therapy Partnering trends in numbers
Partnering in numbers - by year
Partnering in numbers - most active
Partnering in numbers - by industry sector
Partnering in numbers - by deal type
Partnering in numbers - by technology type
Partnering in numbers - by stage of development
Chapter 2 - Most active dealmakers
Chapter 3 - Partnering deals directory
Partnering deals directory - by company A-Z
Partnering deals directory - by deal value
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - by stage of development
Partnering deals directory - by technology area
Chapter 4 - Partnering deals with a contract document
Chapter 5 - M&A in numbers
M&A in numbers - by year
Chapter 6 - M&A deals directory
M&A deals directory - by company A-Z
M&A deals directory - by deal value
Chapter 7 - Financing in numbers
Financing in numbers - by year
Financing in numbers - by financing type
Chapter 8 - Financing deals directory
Financing deals directory - by company A-Z
Financing deals directory - by deal value
Financing deals directory - by financing type
For more information about this report visit https://www.researchandmarkets.com/research/c742cq/global_smoking?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Over the Counter (OTC) Drugs
